Ensysce Biosciences, Inc. - 8-K Filing

Ensysce Biosciences reports Q3 2026 net loss of $82.3 million following $79.9 million non-cash IPR&D charge from Cy Biopharma acquisition (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 21:22 UTC

Tickers: $ENSC

Read the full article at SEC EDGAR

More Regulatory news

Nakamoto Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:35 UTC
enCore Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:34 UTC
Cibus, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:34 UTC
Spero Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:34 UTC
PepGen Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:34 UTC
WhiteHawk Minerals Corp. - 8-K Filing SEC EDGAR · November 12, 2026, 21:34 UTC
Altimmune, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:33 UTC
LifeStance Health Group, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:32 UTC
Net Power Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:31 UTC
FIRST KEYSTONE CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 21:31 UTC